Tecentriq® (atezolizumab): Risk of nephritis

Print

User Rating: 1 / 5

Star ActiveStar InactiveStar InactiveStar InactiveStar Inactive
 


Description:

Healthcare professionals are informed of the new important identified risk of nephritis with use of Tecentriq® (atezolizumab).


Atezolizumab is indicated for the treatment of patients with metastatic non-small cell lung cancer who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have experienced disease progression on approved therapy for these aberrations prior to receiving atezolizumab.

It is recommended that atezolizumab be withheld for moderate (Grade 2) immune-related nephritis, and permanently discontinued for severe nephritis (Grade 3 and 4). Patients should be referred to a renal specialist, considering renal biopsy and supportive measures as indicated. Corticosteroids and/or additional immunosuppressive agents should be administered as clinically indicated.


A Direct Healthcare Professional Communication (DHPC) letter has been issued by Roche (M) Sdn. Bhd. in agreement with NPRA to highlight this safety issue. Please refer to this DHPC for further information.